Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Total Current Liabilities for 14 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 8.81% year-over-year to $44.7 million, compared with a TTM value of $44.7 million through Dec 2025, down 8.81%, and an annual FY2025 reading of $48.6 million, down 15.61% over the prior year.
  • Total Current Liabilities was $44.7 million for Q4 2025 at Enanta Pharmaceuticals, down from $48.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $68.2 million in Q2 2023 and bottomed at $23.0 million in Q4 2022.
  • Average Total Current Liabilities over 5 years is $43.2 million, with a median of $44.6 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities plummeted 39.3% in 2022, then skyrocketed 196.02% in 2023.
  • Year by year, Total Current Liabilities stood at $37.9 million in 2021, then tumbled by 39.3% to $23.0 million in 2022, then soared by 171.32% to $62.4 million in 2023, then fell by 21.4% to $49.0 million in 2024, then fell by 8.81% to $44.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for ENTA at $44.7 million in Q4 2025, $48.6 million in Q3 2025, and $44.5 million in Q2 2025.